$LUDG Highlights from the shareholder letter inclu
Post# of 23600
Ludwig has made exciting changes in the past 4-6 months, including the acquisition of mRNA genomic technology with the potential to revolutionize healthcare.
Ludwig has filed a patent for their Precision Genomics MRNA Inflammatory Index™ and launched a subsidiary, MyRNA for Life, Inc., to market an antioxidant nutraceutical formulation that could modulate inflammatory substances released by immune system cells.
Key milestones and value drivers for 2022 include signing up for the SRAX Shareholder Platform, acquiring assets and launching subsidiaries, filing patents and trademarks, attending conferences such as LD Micro Conference in Los Angeles, CA, meeting with investment banks, and preparation of an IPO filing with law firm MSK, Los Angeles CA & New York NY.
https://www.accesswire.com/732724/Ludwig-Ente...der-Letter